Download Free Sample
Buy Now
Table of Contents
1.1. Context
1.2. Project Objectives
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Value and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Concluding Remarks
6.1. An Overview of Aging in Dogs
6.2. Key Factors Affecting Aging in Dogs
6.3. Symptoms of Aging in Dogs
6.4. Dog Aging Project
6.5. Advancements in Anti-aging Drugs for Dogs
6.6. Future Perspective
7.1. Methodology and Key Parameters
7.2. Anti-Aging Drugs for Dogs: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Type of Molecule
7.2.3. Analysis by Mechanism of Action
7.2.4. Analysis by Biological Target
7.2.5. Analysis by Type of Therapy
7.2.6. Analysis by Dosing Frequency
7.2.7. Analysis by Route of Administration
7.2.8. Analysis by Type of Formulation
7.2.9. Analysis by Type of Aging
7.2.10. Analysis by Target Species
7.3. Developers of Anti-aging Drugs for Dogs
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Type of Developer
8.1. Methodology and Key Parameters
8.2. Scoring Criteria
8.3. Anti-aging Drug Developers for Dogs: Company Competitiveness Analysis
8.4. Key Players
9.1. Loyal
9.1.1. Company Overview
9.1.2. Anti-aging Drugs for Dogs Pipeline
9.1.3. Recent Initiatives and Future Outlook
9.2. Alive
9.3. Genflow Bioscience
9.4. JangoPet
9.5. Rejuvenate Bio
9.6. Telomir Pharmaceuticals
10.1. Partnership Models
10.2. Parameters
10.3. Anti-aging Drugs for Dogs : Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Type of Partner
10.3.5. Most Active Players: Analysis by Number of Partnerships
10.3.6. Analysis by Geography
10.3.6.1. Distribution by Country
10.3.6.2. Distribution by Region
11.1. Funding Models
11.2. Funding Lifecycle Analysis
11.3. Investment Case: Risk and Return
11.4. Anti-aging Drugs for Dogs : Funding and Investments
11.4.1. Analysis of Instances by Year of Funding
11.4.2. Analysis of Instances by Type of Funding
11.4.3. Analysis of Instances by Year and Type of Funding
11.4.4. Analysis of Amount by Year of Funding
11.4.5. Analysis of Amount by Type of Funding
11.4.6. Analysis by Geography
11.4.7. Most Active Players: Analysis by Number of Funding Instances
11.4.8. Most Active Players: Analysis by Amount Invested
11.4.9. Most Active Investors: Analysis by Number of Funding Instances
11.5. Summary
11.6. Key Takeaways
12.1. Methodology
12.2. Parameters
12.3. Anti-aging Drugs for Dogs : Publications
12.3.1. Analysis by Year of Publication
12.3.2. Analysis by Type of Publication
12.3.3. Most Active Publisher: Analysis by Number of Publications
12.3.4. Key Journal: Analysis by Number of Publications
12.3.5. Key Journal: Analysis by Impact Factor
13.1. Methodology
13.2. Parameters
13.3. Anti-aging Drugs for Dogs: Patent Analysis
13.3.1. Analysis by Publication Year
13.3.2. Analysis by Type of Patent
13.3.3. Analysis by Type of Patent and Publication Year
13.3.4. Analysis by Application Year
13.3.5. Analysis by Patent Jurisdiction
13.3.6. Leading Individual Assignees: Analysis by Number of Patents
13.3.7. Analysis by CPC Symbols
13.3.8. Definition of Top CPC Symbols
14.1. Forecast Model
14.2. Key Assumptions
14.3. Forecast Methodology
14.4. Global Anti-Aging Drugs for Dogs Market, Till 2040
14.4.1. Multivariate Scenario Analysis
14.4.1.1. Conservative Scenario
14.4.1.2. Optimistic Scenario
14.5. Key Market Segmentations
15.1. Anti-Aging Drugs for Dogs Market: Distribution by Type of Modality
15.1.1. Anti-Aging Drugs for Dogs Market for Biologics, Forecasted Estimates (Till 2040)
15.1.2. Anti-Aging Drugs for Dogs Market for Small Molecules, Forecasted Estimates (Till 2040)
15.2. Data Triangulation and Validation
16.1. Anti-Aging Drugs for Dogs Market: Distribution by Type of Biologic
16.1.1. Anti-Aging Drugs for Dogs Market for Gene Therapies, Forecasted Estimates (Till 2040)
16.1.2. Anti-Aging Drugs for Dogs Market for Cell Therapies, Forecasted Estimates (Till 2040)
16.1.3. Anti-Aging Drugs for Dogs Market for Antisense Oligonucleotides, Forecasted Estimates (Till 2040)
16.2. Data Triangulation and Validation
17.1. Anti-Aging Drugs for Dogs Market: Distribution by Route of Administration
17.1.1. Anti-Aging Drugs for Dogs Market for Intravenous, Forecasted Estimates (Till 2040)
17.1.2. Anti-Aging Drugs for Dogs Market for Oral, Forecasted Estimates (Till 2040)
17.2. Data Triangulation and Validation
18.1. Anti-Aging Drugs for Dogs Market: Distribution by Type of Formulation
18.1.1. Anti-Aging Drugs for Dogs Market for Injections, Forecasted Estimates (Till 2040)
18.1.2. Anti-Aging Drugs for Dogs Market for Tablets, Forecasted Estimates (Till 2040)
18.2. Data Triangulation and Validation
19.1. Anti-Aging Drugs for Dogs Market: Distribution by Type of Aging
19.1.1. Anti-Aging Drugs for Dogs Market for Metabolic Aging, Forecasted Estimates (Till 2040)
19.1.2. Anti-Aging Drugs for Dogs Market for Cellular Aging, Forecasted Estimates (Till 2040)
19.1.3. Anti-Aging Drugs for Dogs Market for Others, Forecasted Estimates (Till 2040)
19.2. Data Triangulation and Validation
20.1. Anti-Aging Drugs for Dogs Market: Distribution by Type of Canine Population Targeted
20.1.1. Anti-Aging Drugs for Dogs Market for Senior Dogs, Forecasted Estimates (Till 2040)
20.1.2. Anti-Aging Drugs for Dogs Market for Large and Giant Dogs, Forecasted Estimates (Till 2040)
20.1.3. Anti-Aging Drugs for Dogs Market for Other Target Species, Forecasted Estimates (Till 2040)
20.2. Data Triangulation and Validation
21.1. Anti-Aging Drugs for Dogs Market: Distribution by Geographical Regions
21.1.1. Anti-Aging Drugs for Dogs Market in North America, Forecasted Estimates (Till 2040)
21.1.2. Anti-Aging Drugs for Dogs Market in Europe, Forecasted Estimates (Till 2040)
21.1.3. Anti-Aging Drugs for Dogs Market in Asia-Pacific, Forecasted Estimates (Till 2040)
21.1.4. Anti-Aging Drugs for Dogs Market in Middle East and North Africa, Forecasted Estimates (Till 2040)
21.1.5. Anti-Aging Drugs for Dogs Market in Latin America, Forecasted Estimates (Till 2040)
21.2. Data Triangulation and Validation
22.1. Anti-Aging Drugs for Dogs Market in North America: Distribution by Type of Modality
22.1.1. Anti-Aging Drugs for Dogs Market in North America for Small Molecules, Forecasted Estimates (Till 2040)
22.1.2. Anti-Aging Drugs for Dogs Market in North America for Biologics, Forecasted Estimates (Till 2040)
22.2. Anti-Aging Drugs for Dogs Market in North America: Distribution by Type of Biologic
22.2.1. Anti-Aging Drugs for Dogs Market in North America for Gene Therapies, Forecasted Estimates (Till 2040)
22.2.2. Anti-Aging Drugs for Dogs Market in North America for Cell Therapies, Forecasted Estimates (Till 2040)
22.2.3. Anti-Aging Drugs for Dogs Market in North America for Antisense Oligonucleotides, Forecasted Estimates (Till 2040)
22.3. Anti-Aging Drugs for Dogs Market in North America: Distribution by Route of Administration
22.3.1. Anti-Aging Drugs for Dogs Market in North America for Intravenous, Forecasted Estimates (Till 2040)
22.3.2. Anti-Aging Drugs for Dogs Market in North America for Oral, Forecasted Estimates (Till 2040)
22.4. Anti-Aging Drugs for Dogs Market in North America: Distribution by Type of Formulation
22.4.1. Anti-Aging Drugs for Dogs Market in North America for Injections, Forecasted Estimates (Till 2040)
22.4.2. Anti-Aging Drugs for Dogs Market in North America for Tablets, Forecasted Estimates (Till 2040)
22.5. Anti-Aging Drugs for Dogs Market in North America: Distribution by Type of Aging
22.5.1. Anti-Aging Drugs for Dogs Market in North America for Metabolic Aging, Forecasted Estimates (Till 2040)
22.5.2. Anti-Aging Drugs for Dogs Market in North America for Cellular Aging, Forecasted Estimates (Till 2040)
22.5.3. Anti-Aging Drugs for Dogs Market in North America for Others, Forecasted Estimates (Till 2040)
22.6. Anti-Aging Drugs for Dogs Market in North America: Distribution by Type of Canine Population Targeted
22.6.1. Anti-Aging Drugs for Dogs Market in North America for Senior Dogs, Forecasted Estimates (Till 2040)
22.6.2. Anti-Aging Drugs for Dogs Market in North America for Large and Giant Dogs, Forecasted Estimates (Till 2040)
22.6.3. Anti-Aging Drugs for Dogs Market in North America for Other Target Species, Forecasted Estimates (Till 2040)
23.1. Anti-Aging Drugs for Dogs Market in Europe: Distribution by Type of Modality
23.1.1. Anti-Aging Drugs for Dogs Market in Europe for Small Molecules, Forecasted Estimates (Till 2040)
23.1.2. Anti-Aging Drugs for Dogs Market in Europe for Biologics, Forecasted Estimates (Till 2040)
23.2. Anti-Aging Drugs for Dogs Market in Europe: Distribution by Type of Biologic
23.2.1. Anti-Aging Drugs for Dogs Market in Europe for Gene Therapies, Forecasted Estimates (Till 2040)
23.2.2. Anti-Aging Drugs for Dogs Market in Europe for Cell Therapies, Forecasted Estimates (Till 2040)
23.2.3. Anti-Aging Drugs for Dogs Market in Europe for Antisense Oligonucleotides , Forecasted Estimates (Till 2040)
23.3. Anti-Aging Drugs for Dogs Market in Europe: Distribution by Route of Administration
23.3.1. Anti-Aging Drugs for Dogs Market in Europe for Intravenous , Forecasted Estimates (Till 2040)
23.3.2. Anti-Aging Drugs for Dogs Market in Europe for Oral, Forecasted Estimates (Till 2040)
23.4. Anti-Aging Drugs for Dogs Market in Europe: Distribution by Type of Formulation
23.4.1. Anti-Aging Drugs for Dogs Market in Europe for Injections, Forecasted Estimates (Till 2040)
23.4.2. Anti-Aging Drugs for Dogs Market in Europe for Tablets, Forecasted Estimates (Till 2040)
23.5. Anti-Aging Drugs for Dogs Market in Europe: Distribution by Type of Aging
23.5.1. Anti-Aging Drugs for Dogs Market in Europe for Metabolic Aging, Forecasted Estimates (Till 2040)
23.5.2. Anti-Aging Drugs for Dogs Market in Europe for Cellular Aging, Forecasted Estimates (Till 2040)
23.5.3. Anti-Aging Drugs for Dogs Market in Europe for Others, Forecasted Estimates (Till 2040)
23.6. Anti-Aging Drugs for Dogs Market in Europe: Distribution by Type of Canine Population Targeted
23.6.1. Anti-Aging Drugs for Dogs Market in Europe for Senior Dogs, Forecasted Estimates (Till 2040)
23.6.2. Anti-Aging Drugs for Dogs Market in Europe for Large and Giant Dogs, Forecasted Estimates (Till 2040)
23.6.3. Anti-Aging Drugs for Dogs Market in Europe for Other Target Species, Forecasted Estimates (Till 2040)
24.1. Anti-Aging Drugs for Dogs Market in Asia-Pacific: Distribution by Type of Modality
24.1.1. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Small Molecules, Forecasted Estimates (Till 2040)
24.1.2. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Biologics, Forecasted Estimates (Till 2040)
24.2. Anti-Aging Drugs for Dogs Market in Asia-Pacific: Distribution by Type of Biologic
24.2.1. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Gene Therapies, Forecasted Estimates (Till 2040)
24.2.2. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Cell Therapies, Forecasted Estimates (Till 2040)
24.2.3. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Antisense Oligonucleotides, Forecasted Estimates (Till 2040)
24.3. Anti-Aging Drugs for Dogs Market in Asia-Pacific: Distribution by Route of Administration
24.3.1. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Intravenous, Forecasted Estimates (Till 2040)
24.3.2. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Oral, Forecasted Estimates (Till 2040)
24.4. Anti-Aging Drugs for Dogs Market in Asia-Pacific: Distribution by Type of Formulation
24.4.1. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Injections, Forecasted Estimates (Till 2040)
24.4.2. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Tablets, Forecasted Estimates (Till 2040)
24.5. Anti-Aging Drugs for Dogs Market in Asia-Pacific: Distribution by Type of Aging
24.5.1. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Metabolic Aging, Forecasted Estimates (Till 2040)
24.5.2. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Cellular Aging, Forecasted Estimates (Till 2040)
24.5.3. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Others, Forecasted Estimates (Till 2040)
24.6. Anti-Aging Drugs for Dogs Market in Asia-Pacific: Distribution by Type of Canine Population Targeted
24.6.1. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Senior Dogs, Forecasted Estimates (Till 2040)
24.6.2. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Large and Giant Dogs, Forecasted Estimates (Till 2040)
24.6.3. Anti-Aging Drugs for Dogs Market in Asia-Pacific for Other Target Species, Forecasted Estimates (Till 2040)
25.1. Anti-Aging Drugs for Dogs Market in Middle East and North Africa: Distribution by Type of Modality
25.1.1. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Small Molecules, Forecasted Estimates (Till 2040)
25.1.2. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Biologics, Forecasted Estimates (Till 2040)
25.2. Anti-Aging Drugs for Dogs Market in Middle East and North Africa: Distribution by Type of Biologic
25.2.1. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Gene Therapies, Forecasted Estimates (Till 2040)
25.2.2. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Cell Therapies, Forecasted Estimates (Till 2040)
25.2.3. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Antisense Oligonucleotides, Forecasted Estimates (Till 2040)
25.3. Anti-Aging Drugs for Dogs Market in Middle East and North Africa: Distribution by Route of Administration
25.3.1. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Intravenous, Forecasted Estimates (Till 2040)
25.3.2. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Oral, Forecasted Estimates (Till 2040)
25.4. Anti-Aging Drugs for Dogs Market in Middle East and North Africa: Distribution by Type of Formulation
25.4.1. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Injections, Forecasted Estimates (Till 2040)
25.4.2. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Tablets, Forecasted Estimates (Till 2040)
25.5. Anti-Aging Drugs for Dogs Market in Middle East and North Africa: Distribution by Type of Aging
25.5.1. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Metabolic Aging, Forecasted Estimates (Till 2040)
25.5.2. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Cellular Aging, Forecasted Estimates (Till 2040)
25.5.3. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Others, Forecasted Estimates (Till 2040)
25.6. Anti-Aging Drugs for Dogs Market in Middle East and North Africa: Distribution by Type of Canine Population Targeted
25.6.1. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Senior Dogs, Forecasted Estimates (Till 2040)
25.6.2. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Large and Giant Dogs, Forecasted Estimates (Till 2040)
25.6.3. Anti-Aging Drugs for Dogs Market in Middle East and North Africa for Other Target Species, Forecasted Estimates (Till 2040)
26.1. Anti-Aging Drugs for Dogs Market in Latin America: Distribution by Type of Modality
26.1.1. Anti-Aging Drugs for Dogs Market in Latin America for Small Molecules, Forecasted Estimates (Till 2040)
26.1.2. Anti-Aging Drugs for Dogs Market in Latin America for Biologics, Forecasted Estimates (Till 2040)
26.2. Anti-Aging Drugs for Dogs Market in Latin America: Distribution by Type of Biologic
26.2.1. Anti-Aging Drugs for Dogs Market in Latin America for Gene Therapies, Forecasted Estimates (Till 2040)
26.2.2. Anti-Aging Drugs for Dogs Market in Latin America for Cell Therapies, Forecasted Estimates (Till 2040)
26.2.3. Anti-Aging Drugs for Dogs Market in Latin America for Antisense Oligonucleotides, Forecasted Estimates (Till 2040)
26.3. Anti-Aging Drugs for Dogs Market in Latin America: Distribution by Route of Administration
26.3.1. Anti-Aging Drugs for Dogs Market in Latin America for Intravenous, Forecasted Estimates (Till 2040)
26.3.2. Anti-Aging Drugs for Dogs Market in Latin America for Oral, Forecasted Estimates (Till 2040)
26.4. Anti-Aging Drugs for Dogs Market in Latin America: Distribution by Type of Formulation
26.4.1. Anti-Aging Drugs for Dogs Market in Latin America for Injections, Forecasted Estimates (Till 2040)
26.4.2. Anti-Aging Drugs for Dogs Market in Latin America for Tablets, Forecasted Estimates (Till 2040)
26.5. Anti-Aging Drugs for Dogs Market in Latin America: Distribution by Type of Aging
26.5.1. Anti-Aging Drugs for Dogs Market in Latin America for Metabolic Aging, Forecasted Estimates (Till 2040)
26.5.2. Anti-Aging Drugs for Dogs Market in Latin America for Cellular Aging, Forecasted Estimates (Till 2040)
26.5.3. Anti-Aging Drugs for Dogs Market in Latin America for Others, Forecasted Estimates (Till 2040)
26.6. Anti-Aging Drugs for Dogs Market in Latin America: Distribution by Type of Canine Population Targeted
26.6.1. Anti-Aging Drugs for Dogs Market in Latin America for Senior Dogs, Forecasted Estimates (Till 2040)
26.6.2. Anti-Aging Drugs for Dogs Market in Latin America for Large and Giant Dogs, Forecasted Estimates (Till 2040)
26.6.3. Anti-Aging Drugs for Dogs Market in Latin America for Other Target Species, Forecasted Estimates (Till 2040)
27.1. Anti-Aging Drugs for Dogs Market: Sales Forecast
27.1.1. LOY-002: Sales Forecast
27.1.2. LOY-003: Sales Forecast
27.1.3. LOY-001: Sales Forecast
27.1.4. GF-1004: Sales Forecast
27.1.5. Telomir-1: Sales Forecast
27.1.6. Alive Gene Therapy: Sales Forecast
27.1.7. RJB-01: Sales Forecast
27.1.8. RJB-02: Sales Forecast
27.1.9. Unnamed (Rejuvenate Bio): Sales Forecast
27.1.10. Jango-Relieve: Sales Forecast
27.1.11. Jango-Renew: Sales Forecast
27.1.12. Jango-Org-C1: Sales Forecast
28.1. Chapter Overview
28.2. Methodology
28.3. Key Parameters
28.3.1. Threats of New Entrants
28.3.2. Bargaining Power of Buyers
28.3.3. Bargaining Power of Developers
28.3.4. Threat of Substitute Products
28.3.5. Rivalry Among Existing Competitors
28.4. Conclusion
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 3.3 Market Dynamics: Example List of Parameters
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 7.1 Anti-aging Drugs for Dogs: Distribution by Stage of Development
Figure 7.2 Anti-aging Drugs for Dogs: Distribution by Type of Molecule
Figure 7.3 Anti-aging Drugs for Dogs: Distribution by Mechanism of Action
Figure 7.4 Anti-aging Drugs for Dogs: Distribution by Biological Target
Figure 7.5 Anti-aging Drugs for Dogs: Distribution by Type of Therapy
Figure 7.6 Anti-aging Drugs for Dogs: Distribution by Dosing Frequency
Figure 7.7 Anti-aging Drugs for Dogs: Distribution by Route of Administration
Figure 7.8 Anti-aging Drugs for Dogs: Distribution by Type of Formulation
Figure 7.9 Anti-aging Drugs for Dogs: Distribution by Type of Aging
Figure 7.10 Anti-aging Drugs for Dogs: Distribution by Target Species
Figure 7.11 Developers of Anti-aging Drugs for Dogs: Distribution by Year of Establishment
Figure 7.12 Developers of Anti-aging Drugs for Dogs: Distribution by Developer Size
Figure 7.13 Developers of Anti-aging Drugs for Dogs: Distribution by Location of Headquarters
Figure 7.14 Developers of Anti-aging Drugs for Dogs: Distribution by Type of Developer
Figure 8.1 Company Competitiveness Analysis: Anti-aging Drug Developers for Dogs
Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.5 Most Active Players: Distribution by Number of Partnerships
Figure 10.6 Partnerships and Collaborations: Distribution by Country
Figure 10.7 Partnerships and Collaborations: Distribution by Region
Figure 11.1 Funding and Investments: Funding Lifecycle Analysis
Figure 11.2 Funding and Investments: Distribution of Instances by Year of Funding
Figure 11.3 Funding and Investments: Distribution of Instances by Type of Funding
Figure 11.4 Funding and Investments: Distribution of Instances by Year and Type of Funding
Figure 11.5 Funding and Investments: Distribution of Amount by Year of Funding
Figure 11.6 Funding and Investments: Distribution of Amount by Type of Funding
Figure 11.7 Funding and Investments: Distribution of Funding Instances by Geography
Figure 11.8 Most Active Players: Distribution by Number of Instances
Figure 11.9 Most Active Players: Distribution by Amount Invested
Figure 11.10 Most Active Investors: Distribution by Number of Funding Instances
Figure 11.11 Funding and Investments: Summary
Figure 12.1 Publication Analysis: Distribution by Year of Publication
Figure 12.2 Publication Analysis: Distribution by Type of Publication
Figure 12.3 Most Active Publisher: Distribution by Number of Publications
Figure 12.4 Key Journal: Distribution by Number of Publications
Figure 12.5 Key Journal: Distribution by Impact Factor
Figure 13.1 Patent Analysis: Distribution by Publication Year
Figure 13.2 Patent Analysis: Distribution by Type of Patent
Figure 13.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 13.4 Patent Analysis: Distribution by Application Year
Figure 13.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 13.6 Leading Individual Assignees: Distribution by Number of Patents
Figure 13.7 Patent Analysis: Distribution by CPC Symbols
Figure 14.1 Anti-Aging Drugs for Dogs Market, Base Scenario: Forecasted Estimates (Till 2040) (USD Million)
Figure 14.2 Anti-Aging Drugs for Dogs Market, Conservative Scenario: Forecasted Estimates (Till 2040) (USD Million)
Figure 14.3 Anti-Aging Drugs for Dogs Market, Optimistic Scenario: Forecasted Estimates (Till 2040) (USD Million)
Figure 15.1 Anti-Aging Drugs for Dogs Market: Distribution by Type of Modality
Figure 15.2 Anti-Aging Drugs for Dogs Market for Biologics, Forecasted Estimates (Till 2040) (USD Million)
Figure 15.3 Anti-Aging Drugs for Dogs Market for Small Molecules, Forecasted Estimates (Till 2040) (USD Million)
Figure 16.1 Anti-Aging Drugs for Dogs Market: Distribution by Type of Biologic
Figure 16.2 Anti-Aging Drugs for Dogs Market for Cell Therapies, Forecasted Estimates (Till 2040) (USD Million)
Figure 16.3 Anti-Aging Drugs for Dogs Market for Gene Therapies, Forecasted Estimates (Till 2040) (USD Million)
Figure 16.4 Anti-Aging Drugs for Dogs Market for Antisense Oligonucleotides, Forecasted Estimates (Till 2040) (USD Million)
Figure 17.1 Anti-Aging Drugs for Dogs Market: Distribution by Route of Administration
Figure 17.2 Anti-Aging Drugs for Dogs Market for Oral, Forecasted Estimates (Till 2040) (USD Million)
Figure 17.3 Anti-Aging Drugs for Dogs Market for Intravenous, Forecasted Estimates (Till 2040) (USD Million)
Figure 18.1 Anti-Aging Drugs for Dogs Market: Distribution by Type of Formulation
Figure 18.2 Anti-Aging Drugs for Dogs Market for Injections, Forecasted Estimates (Till 2040) (USD Million)
Figure 18.3 Anti-Aging Drugs for Dogs Market for Tablets, Forecasted Estimates (Till 2040) (USD Million)
Figure 19.1 Anti-Aging Drugs for Dogs Market: Distribution by Type of Aging
Figure 19.2 Anti-Aging Drugs for Dogs Market for Metabolic Aging, Forecasted Estimates (Till 2040) (USD Million)
Figure 19.3 Anti-Aging Drugs for Dogs Market for Cellular Aging, Forecasted Estimates (Till 2040) (USD Million)
Figure 19.4 Anti-Aging Drugs for Dogs Market for Others, Forecasted Estimates (Till 2040) (USD Million)
Figure 20.1 Anti-Aging Drugs for Dogs Market: Distribution by Type of Canine Population Targeted
Figure 20.2 Anti-Aging Drugs for Dogs Market for Senior Dogs, Forecasted Estimates (Till 2040) (USD Million)
Figure 20.3 Anti-Aging Drugs for Dogs Market for Large and Giant Dogs, Forecasted Estimates (Till 2040) (USD Million)
Figure 20.4 Anti-Aging Drugs for Dogs Market for Other Target Species, Forecasted Estimates (Till 2040) (USD Million)
Figure 21.1 Anti-Aging Drugs for Dogs Market: Distribution by Geographical Regions
Figure 21.2 Anti-Aging Drugs for Dogs Market in North America, Forecasted Estimates (Till 2040) (USD Million)
Figure 21.3 Anti-Aging Drugs for Dogs Market in Europe, Forecasted Estimates (Till 2040) (USD Million)
Figure 21.4 Anti-Aging Drugs for Dogs Market in Asia-Pacific, Forecasted Estimates (Till 2040) (USD Million)
Figure 21.5 Anti-Aging Drugs for Dogs Market in Middle East and North Africa, Forecasted Estimates (Till 2040) (USD Million)
Figure 21.6 Anti-Aging Drugs for Dogs Market in Latin America, Forecasted Estimates (Till 2040) (USD Million)
Figure 22.1 LOY-002: Sales Forecast (USD Million)
Figure 22.2 LOY-003: Sales Forecast (USD Million)
Figure 22.3 LOY-001: Sales Forecast (USD Million)
Figure 22.4 GF-1004: Sales Forecast (USD Million)
Figure 22.5 Telomir-1: Sales Forecast (USD Million)
Figure 22.6 Alive Gene Therapy: Sales Forecast (USD Million)
Figure 22.7 RJB-01: Sales Forecast (USD Million)
Figure 22.8 RJB-02: Sales Forecast (USD Million)
Figure 22.9 Unnamed (Rejuvenate Bio): Sales Forecast (USD Million)
Figure 22.10 Jango-Relieve: Sales Forecast (USD Million)
Figure 22.11 Jango-Renew: Sales Forecast (USD Million)
Figure 22.12 Jango-Org-C1: Sales Forecast (USD Million)
Figure 23.1 Porter’s Five Forces: Conclusion
Table 7.1 List of Anti-aging Drugs for Dogs
Table 7.2 Anti-aging Drugs for Dogs: List of Developers
Table 9.1 Alive: Anti-aging Drugs for Dogs Pipeline
Table 9.2 Genflow Bioscience: Anti-aging Drugs for Dogs Pipeline
Table 9.3 Jangopet: Anti-aging Drugs for Dogs Pipeline
Table 9.4 Loyal: Anti-aging Drugs for Dogs Pipeline
Table 9.5 Rejuvenate Bio: Anti-aging Drugs for Dogs Pipeline
Table 9.6 Telomir Pharmaceuticals: Anti-aging Drugs for Dogs Pipeline
Table 10.1 Anti-aging Drugs for Dogs: List of Partnerships and Collaborations, Since 2021
Table 11.1 Anti-aging Drugs for Dogs: List of Funding and Investments, Since 2021
Table 12.1 Anti-aging Drugs for Dogs: List of Publications, Since 2016
Table 13.1 Anti-aging Drugs for Dogs: List of Published Patents, Since 2020
Table 14.1 Anti-aging Drugs for Dogs Market: List of Forecasted Drugs
Table 22.1 Anti-aging Drugs for Dogs Market in North America for Type of Modality, Forecasted Estimates (till 2040) (USD Million)
Table 22.2 Anti-aging Drugs for Dogs Market in North America for Type of Biologic, Forecasted Estimates (till 2040) (USD Million)
Table 22.3 Anti-aging Drugs for Dogs Market in North America for Route of Administration, Forecasted Estimates (till 2040) (USD Million)
Table 22.4 Anti-aging Drugs for Dogs Market in North America for Type of Formulation, Forecasted Estimates (till 2040) (USD Million)
Table 22.5 Anti-aging Drugs for Dogs Market in North America for Type of Aging, Forecasted Estimates (till 2040) (USD Million)
Table 22.6 Anti-aging Drugs for Dogs Market in North America for Type of Canine Population Targeted, Forecasted Estimates (till 2040) (USD Million)
Table 23.1 Anti-aging Drugs for Dogs Market in Europe for Type of Modality, Forecasted Estimates (till 2040) (USD Million)
Table 23.2 Anti-aging Drugs for Dogs Market in Europe for Type of Biologic, Forecasted Estimates (till 2040) (USD Million)
Table 23.3 Anti-aging Drugs for Dogs Market in Europe for Route of Administration, Forecasted Estimates (till 2040) (USD Million)
Table 23.4 Anti-aging Drugs for Dogs Market in Europe for Type of Formulation, Forecasted Estimates (till 2040) (USD Million)
Table 23.5 Anti-aging Drugs for Dogs Market in Europe for Type of Aging, Forecasted Estimates (till 2040) (USD Million)
Table 23.6 Anti-aging Drugs for Dogs Market in Europe for Type of Canine Population Targeted, Forecasted Estimates (till 2040) (USD Million)
Table 24.1 Anti-aging Drugs for Dogs Market in Asia-Pacific for Type of Modality, Forecasted Estimates (till 2040) (USD Million)
Table 24.2 Anti-aging Drugs for Dogs Market in Asia-Pacific for Type of Biologic, Forecasted Estimates (till 2040) (USD Million)
Table 24.3 Anti-aging Drugs for Dogs Market in Asia-Pacific for Route of Administration, Forecasted Estimates (till 2040) (USD Million)
Table 24.4 Anti-aging Drugs for Dogs Market in Asia-Pacific for Type of Formulation, Forecasted Estimates (till 2040) (USD Million)
Table 24.5 Anti-aging Drugs for Dogs Market in Asia-Pacific for Type of Aging, Forecasted Estimates (till 2040) (USD Million)
Table 24.6 Anti-aging Drugs for Dogs Market in Asia-Pacific for Type of Canine Population Targeted, Forecasted Estimates (till 2040) (USD Million)
Table 25.1 Anti-aging Drugs for Dogs Market in Middle East and North Africa for Type of Modality, Forecasted Estimates (till 2040) (USD Million)
Table 25.2 Anti-aging Drugs for Dogs Market in Middle East and North Africa for Type of Biologic, Forecasted Estimates (till 2040) (USD Million)
Table 25.3 Anti-aging Drugs for Dogs Market in Middle East and North Africa for Route of Administration, Forecasted Estimates (till 2040) (USD Million)
Table 25.4 Anti-aging Drugs for Dogs Market in Middle East and North Africa for Type of Formulation, Forecasted Estimates (till 2040) (USD Million)
Table 25.5 Anti-aging Drugs for Dogs Market in Middle East and North Africa for Type of Aging, Forecasted Estimates (till 2040) (USD Million)
Table 25.6 Anti-aging Drugs for Dogs Market in Middle East and North Africa for Type of Canine Population Targeted, Forecasted Estimates (till 2040) (USD Million)
Table 26.1 Anti-aging Drugs for Dogs Market in Latin America for Type of Modality, Forecasted Estimates (till 2040) (USD Million)
Table 26.2 Anti-aging Drugs for Dogs Market in Latin America for Type of Biologic, Forecasted Estimates (till 2040) (USD Million)
Table 26.3 Anti-aging Drugs for Dogs Market in Latin America for Route of Administration, Forecasted Estimates (till 2040) (USD Million)
Table 26.4 Anti-aging Drugs for Dogs Market in Latin America for Type of Formulation, Forecasted Estimates (till 2040) (USD Million)
Table 26.5 Anti-aging Drugs for Dogs Market in Latin America for Type of Aging, Forecasted Estimates (till 2040) (USD Million)
Table 26.6 Anti-aging Drugs for Dogs Market in Latin America for Type of Canine Population Targeted, Forecasted Estimates (till 2040) (USD Million)
**Detailed information on Tables 22.1-26.6 is available in the Excel Data Packs shared along with the report**
Table 30.1 Anti-aging Drugs for Dogs : Distribution by Stage of Development
Table 30.2 Anti-aging Drugs for Dogs : Distribution by Type of Molecule
Table 30.3 Anti-aging Drugs for Dogs : Distribution by Mechanism of Action
Table 30.4 Anti-aging Drugs for Dogs : Distribution by Biological Target
Table 30.5 Anti-aging Drugs for Dogs : Distribution by Type of Therapy
Table 30.6 Anti-aging Drugs for Dogs : Distribution by Dosing Frequency
Table 30.7 Anti-aging Drugs for Dogs : Distribution by Route of Administration
Table 30.8 Anti-aging Drugs for Dogs : Distribution by Type of Formulation
Table 30.9 Anti-aging Drugs for Dogs : Distribution by Type of Aging
Table 30.10 Anti-aging Drugs for Dogs : Distribution by Target Species
Table 30.11 Developers of Anti-aging Drugs for Dogs : Distribution by Year of Establishment
Table 30.12 Developers of Anti-aging Drugs for Dogs : Distribution by Developer Size
Table 30.13 Developers of Anti-aging Drugs for Dogs : Distribution by Location of Headquarters
Table 30.14 Developers of Anti-aging Drugs for Dogs : Distribution by Type of Developer
Table 30.15 Partnerships and Collaborations: Distribution by Year of Partnership
Table 30.16 Partnerships and Collaborations: Distribution by Type of Partnership
Table 30.17 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 30.18 Partnerships and Collaborations: Distribution by Type of Partner
Table 30.19 Most Active Players: Distribution by Number of Partnerships
Table 30.20 Partnerships and Collaborations: Distribution by Country
Table 30.21 Partnerships and Collaborations: Distribution by Region
Table 30.22 Funding and Investments: Funding Lifecycle Analysis
Table 30.23 Funding and Investments: Distribution of Instances by Year of Funding
Table 30.24 Funding and Investments: Distribution of Instances by Type of Funding
Table 30.25 Funding and Investments: Distribution of Instances by Year and Type of Funding
Table 30.26 Funding and Investments: Distribution of Amount by Year of Funding
Table 30.27 Funding and Investments: Distribution of Amount by Type of Funding
Table 30.28 Funding and Investments: Distribution of Funding Instances by Geography
Table 30.29 Most Active Players: Distribution by Number of Instances
Table 30.30 Most Active Players: Distribution by Amount Invested
Table 30.31 Most Active Investors: Distribution by Number of Funding Instances
Table 30.32 Publication Analysis: Distribution by Year of Publication
Table 30.33 Publication Analysis: Distribution by Type of Publication
Table 30.34 Most Active Publisher: Distribution by Number of Publications
Table 30.35 Key Journal: Distribution by Number of Publications
Table 30.36 Key Journal: Distribution by Impact Factor
Table 30.37 Patent Analysis: Distribution by Publication Year
Table 30.38 Patent Analysis: Distribution by Type of Patent
Table 30.39 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 30.40 Patent Analysis: Distribution by Application Year
Table 30.41 Patent Analysis: Distribution by Patent Jurisdiction
Table 30.42 Leading Individual Assignees: Distribution by Number of Patents
Table 30.43 Patent Analysis: Distribution by CPC Symbols
Table 30.44 Anti-Aging Drugs for Dogs Market, Base Scenario: Forecasted Estimates (Till 2040) (USD Million)
Table 30.45 Anti-Aging Drugs for Dogs Market, Conservative Scenario: Forecasted Estimates (Till 2040) (USD Million)
Table 30.46 Anti-Aging Drugs for Dogs Market, Optimistic Scenario: Forecasted Estimates (Till 2040) (USD Million)
Table 30.47 Anti-Aging Drugs for Dogs Market: Distribution by Type of Modality
Table 30.48 Anti-Aging Drugs for Dogs Market for Biologics, Forecasted Estimates (Till 2040) (USD Million)
Table 30.49 Anti-Aging Drugs for Dogs Market for Small Molecules, Forecasted Estimates (Till 2040) (USD Million)
Table 30.50 Anti-Aging Drugs for Dogs Market: Distribution by Type of Biologic
Table 30.51 Anti-Aging Drugs for Dogs Market for Cell Therapies, Forecasted Estimates (Till 2040) (USD Million)
Table 30.52 Anti-Aging Drugs for Dogs Market for Gene Therapies, Forecasted Estimates (Till 2040) (USD Million)
Table 30.53 Anti-Aging Drugs for Dogs Market for Antisense Oligonucleotides, Forecasted Estimates (Till 2040) (USD Million)
Table 30.54 Anti-Aging Drugs for Dogs Market: Distribution by Route of Administration
Table 30.55 Anti-Aging Drugs for Dogs Market for Intravenous, Forecasted Estimates (Till 2040) (USD Million)
Table 30.56 Anti-Aging Drugs for Dogs Market for Oral, Forecasted Estimates (Till 2040) (USD Million)
Table 30.57 Anti-Aging Drugs for Dogs Market: Distribution by Type of Formulation
Table 30.58 Anti-Aging Drugs for Dogs Market for Injections, Forecasted Estimates (Till 2040) (USD Million)
Table 30.59 Anti-Aging Drugs for Dogs Market for Tablets, Forecasted Estimates (Till 2040) (USD Million)
Table 30.60 Anti-Aging Drugs for Dogs Market: Distribution by Type of Aging
Table 30.61 Anti-Aging Drugs for Dogs Market for Metabolic Aging, Forecasted Estimates (Till 2040) (USD Million)
Table 30.62 Anti-Aging Drugs for Dogs Market for Cellular Aging, Forecasted Estimates (Till 2040) (USD Million)
Table 30.63 Anti-Aging Drugs for Dogs Market for Others, Forecasted Estimates (Till 2040) (USD Million)
Table 30.64 Anti-Aging Drugs for Dogs Market: Distribution by Type of Canine Population Targeted
Table 30.65 Anti-Aging Drugs for Dogs Market for Senior Dogs, Forecasted Estimates (Till 2040) (USD Million)
Table 30.66 Anti-Aging Drugs for Dogs Market for Large and Giant Dogs, Forecasted Estimates (Till 2040) (USD Million)
Table 30.67 Anti-Aging Drugs for Dogs Market for Other Target Species, Forecasted Estimates (Till 2040) (USD Million)
Table 30.68 Anti-Aging Drugs for Dogs Market: Distribution by Geographical Regions
Table 30.69 Anti-Aging Drugs for Dogs Market in North America, Forecasted Estimates (Till 2040) (USD Million)
Table 30.70 Anti-Aging Drugs for Dogs Market in Europe, Forecasted Estimates (Till 2040) (USD Million)
Table 30.71 Anti-Aging Drugs for Dogs Market in Asia-Pacific, Forecasted Estimates (Till 2040) (USD Million)
Table 30.72 Anti-Aging Drugs for Dogs Market in Middle East and North Africa, Forecasted Estimates (Till 2040) (USD Million)
Table 30.73 Anti-Aging Drugs for Dogs Market in Latin America, Forecasted Estimates (Till 2040) (USD Million)
Table 30.74 LOY-002: Sales Forecast (USD Million)
Table 30.75 LOY-003: Sales Forecast (USD Million)
Table 30.76 LOY-001: Sales Forecast (USD Million)
Table 30.77 GF-1004: Sales Forecast (USD Million)
Table 30.78 Telomir-1: Sales Forecast (USD Million)
Table 30.79 Alive Gene Therapy: Sales Forecast (USD Million)
Table 30.80 RJB-01: Sales Forecast (USD Million)
Table 30.81 RJB-02: Sales Forecast (USD Million)
Table 30.82 Unnamed (Rejuvenate Bio): Sales Forecast (USD Million)
Table 30.83 Jango-Relieve: Sales Forecast (USD Million)
Table 30.84 Jango-Renew: Sales Forecast (USD Million)
Table 30.85 Jango-Org-C1: Sales Forecast (USD Million)